Xiaofan Gu

639 total citations
25 papers, 459 citations indexed

About

Xiaofan Gu is a scholar working on Molecular Biology, Physiology and Cancer Research. According to data from OpenAlex, Xiaofan Gu has authored 25 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 10 papers in Physiology and 5 papers in Cancer Research. Recurrent topics in Xiaofan Gu's work include Nutrition and Health in Aging (9 papers), Muscle Physiology and Disorders (7 papers) and MicroRNA in disease regulation (4 papers). Xiaofan Gu is often cited by papers focused on Nutrition and Health in Aging (9 papers), Muscle Physiology and Disorders (7 papers) and MicroRNA in disease regulation (4 papers). Xiaofan Gu collaborates with scholars based in China and United States. Xiaofan Gu's co-authors include Xiongwen Zhang, Xuan Liu, Wanli Zhang, Qiang Shen, Li‐Xing Feng, Meng Fan, Chunxiao Miao, Hui Wang, Yu‐Shui Ma and Shanshan Lu and has published in prestigious journals such as Biochemical and Biophysical Research Communications, European Journal of Pharmacology and Toxicology and Applied Pharmacology.

In The Last Decade

Xiaofan Gu

24 papers receiving 453 citations

Peers

Xiaofan Gu

PHYSI

ONCOL

IMMUN

Doo Jae Lee South Korea

Anita Boratkó Hungary

Yonghwan Shin South Korea

Annie Demers Canada

Robert Roth Sweden

Lu Hu China

Melissa Van Arsdall United States

Nadja Ring Italy

Lele Li China

Doo Jae Lee South Korea

Xiaofan Gu

405 ×1.4

54 ×0.4

PHYSI

71 ×0.7

31 ×0.7

ONCOL

71 ×1.6

IMMUN

Citations per year, relative to Xiaofan Gu Xiaofan Gu (= 1×) peers Doo Jae Lee

Countries citing papers authored by Xiaofan Gu

Since Specialization

Citations

This map shows the geographic impact of Xiaofan Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaofan Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaofan Gu more than expected).

Fields of papers citing papers by Xiaofan Gu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaofan Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaofan Gu. The network helps show where Xiaofan Gu may publish in the future.

Co-authorship network of co-authors of Xiaofan Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaofan Gu. A scholar is included among the top collaborators of Xiaofan Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaofan Gu. Xiaofan Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Cong, Xiaofan Gu, Xiaojuan Pan, et al.. (2025). Ruxolitinib alleviated muscle atrophy in cancer cachexia by inhibiting IL-6/JAK/STAT3 signaling pathway in mice. Journal of Pharmacy and Pharmacology. 77(12). 1715–1725.

Wu, Tingting, et al.. (2025). Endothelial Activation and Stress Index Predicts All‐Cause and Cardiovascular Mortality in Hypertensive Individuals: A Nationwide Study. Journal of Clinical Hypertension. 27(4). e70057–e70057. 3 indexed citations

Gu, Xiaofan, Shanshan Lu, Meng Fan, et al.. (2024). Compound Z526 alleviates chemotherapy-induced cachectic muscle loss by ameliorating oxidative stress-driven protein metabolic imbalance and apoptosis. European Journal of Pharmacology. 974. 176538–176538. 4 indexed citations

Gu, Xiaofan, Shanshan Lu, Yiwei Li, et al.. (2024). Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress. Genes & Diseases. 12(2). 101292–101292. 1 indexed citations

Li, Cong, Xiaofan Gu, Xiaoting Wang, et al.. (2024). Paeoniflorin alleviated muscle atrophy in cancer cachexia through inhibiting TLR4/NF-κB signaling and activating AKT/mTOR signaling. Toxicology and Applied Pharmacology. 484. 116846–116846. 6 indexed citations

Gu, Xiaofan, et al.. (2024). Neutrophil-lymphocyte ratio is a predictor for all-cause and cardiovascular mortality in individuals with prediabetes in a National study. Endocrine. 87(2). 589–598. 3 indexed citations

Pan, Xiaojuan, Gang Zhang, Kun Wei, et al.. (2023). Carnosol analogue WK-63 alleviated cancer cachexia by inhibiting NF-κB and activating AKT pathways in muscle while inhibiting NF-κB and AMPK pathways in adipocyte. Toxicology and Applied Pharmacology. 479. 116729–116729. 3 indexed citations

Zhang, Ruiqin, Qiang Shen, Xue Deng, et al.. (2023). Corylifol A ameliorates muscle atrophy by inhibiting TAOK1/p38‐MAPK/FoxO3 pathway in cancer cachexia. Journal of Cachexia Sarcopenia and Muscle. 14(5). 2098–2113. 14 indexed citations

Fan, Meng, Xiaofan Gu, Wanli Zhang, et al.. (2022). Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL‐6 and tumour‐derived extracellular vesicles. Journal of Cachexia Sarcopenia and Muscle. 13(6). 2724–2739. 37 indexed citations

10.

Zhang, Wanli, Xiaofan Gu, Chunxiao Miao, et al.. (2022). GDF-15 in tumor-derived exosomes promotes muscle atrophy via Bcl-2/caspase-3 pathway. Cell Death Discovery. 8(1). 162–162. 42 indexed citations

11.

Miao, Chunxiao, Wanli Zhang, Li‐Xing Feng, et al.. (2021). Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Molecular Therapy — Nucleic Acids. 24. 923–938. 60 indexed citations

12.

Lu, Shanshan, Yiwei Li, Qiang Shen, et al.. (2021). Carnosol and its analogues attenuate muscle atrophy and fat lipolysis induced by cancer cachexia. Journal of Cachexia Sarcopenia and Muscle. 12(3). 779–795. 37 indexed citations

13.

Zhang, Caiyun, et al.. (2021). Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo. Clinical & Translational Oncology. 23(8). 1549–1560. 6 indexed citations

14.

Feng, Li‐Xing, Wanli Zhang, Qiang Shen, et al.. (2021). Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome. Journal of Cachexia Sarcopenia and Muscle. 12(6). 1553–1569. 61 indexed citations

15.

Zhang, Wanli, et al.. (2021). Autophagy inhibition and microRNA‑199a‑5p upregulation in paclitaxel‑resistant A549/T lung cancer cells. Oncology Reports. 46(1). 21 indexed citations

16.

Wang, Haili, Yunzhong Chen, Xiaofan Gu, et al.. (2020). Design, synthesis, and structure activity relationship (SAR) studies of novel imidazo[1,2-a] pyridine derivatives as Nek2 inhibitors. Bioorganic & Medicinal Chemistry. 28(23). 115775–115775. 9 indexed citations

17.

Li, Yalei, Yushu Huang, Minmin Zhang, et al.. (2020). Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging. Journal of Materials Chemistry B. 8(9). 1878–1896. 5 indexed citations

18.

Gu, Xiaofan, et al.. (2020). Fine-Grained Action Recognition on a Novel Basketball Dataset. 17 indexed citations

19.

Zhang, Caiyun, et al.. (2019). Recombinant cucurmosin-based immunotoxin targeting HER-2 with potent in vitro anti-cancer cytotoxicity. Biochemical and Biophysical Research Communications. 513(1). 15–21. 7 indexed citations

20.

Ma, Xinhua, Weimin Zheng, Xiaofan Gu, et al.. (2018). Two new phenylspirodrimanes from the deep-sea derived fungus Stachybotrys sp. MCCC 3A00409. Natural Product Research. 33(3). 386–392. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact